drugset / Trial / NCT03844932
A Study Evaluating the Efficacy and Safety of ST-0529 in Subjects With Moderately to Severely Active Ulcerative Colitis
RandomizedParallel-groupTriple-blindTreatment
Summary
Study CYC-202 is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of ST-0529 in subjects with moderately to severely active UC, defined as a score of 5 to 9 on the 3-Component Adapted Mayo Score (comprised of rectal bleeding, stool frequency and endoscopy sub-scores; score range 0-9).
Timeline
- Start
- 2019-01-24
- Primary completion
- 2021-04-14
- Completion
- 2021-04-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cyclosporine | Peptide | 18.75 mg | Oral |
| Subject | Cyclosporine | Peptide | 37.5 mg | Oral |
| Subject | Cyclosporine | Peptide | 75 mg | Oral |